@Article{Owczarczyk-Saczonek2013,
journal="Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii",
issn="1642-395X",
volume="30",
number="3",
year="2013",
title="Case reportAcneiform rash during lung cancer therapy with erlotinib (Tarceva®)",
abstract="Tyrosine kinase inhibitors are currently applied in the treatment of non-small cell lung cancer with overexpressed epidermal growth factor receptor (EGFR). Acneiform rash is the earliest and most characteristic side effect of EGFR inhibition. The incidence may be as high as 50-100% of cases. We report a case of a 47-year-old patient who developed acneiform rash after 1.5 weeks of treatment with erlotinib.",
author="Owczarczyk-Saczonek, Agnieszka
and Witmanowski, Henryk
and Placek, Waldemar",
pages="195--198",
doi="10.5114/pdia.2013.35624",
url="http://dx.doi.org/10.5114/pdia.2013.35624"
}